As of 2025-06-16, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -13.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 400.87 mil USD. MYGN's TTM EBITDA according to its financial statements is -29.80 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 11.5x | 9.9x |
| Forward P/E multiples | 10.7x - 12.0x | 11.6x |
| Fair Price | (2.76) - (3.04) | (2.78) |
| Upside | -155.0% - -160.4% | -155.2% |
| Date | EV/EBITDA |
| 2025-06-13 | -13.45 |
| 2025-06-12 | -13.95 |
| 2025-06-11 | -13.92 |
| 2025-06-10 | -14.07 |
| 2025-06-09 | -13.95 |
| 2025-06-06 | -13.64 |
| 2025-06-05 | -13.11 |
| 2025-06-04 | -14.26 |
| 2025-06-03 | -12.99 |
| 2025-06-02 | -11.69 |
| 2025-05-30 | -10.85 |
| 2025-05-29 | -10.76 |
| 2025-05-28 | -11.29 |
| 2025-05-27 | -10.73 |
| 2025-05-23 | -9.99 |
| 2025-05-22 | -10.05 |
| 2025-05-21 | -10.48 |
| 2025-05-20 | -11.66 |
| 2025-05-19 | -11.60 |
| 2025-05-16 | -10.67 |
| 2025-05-15 | -10.61 |
| 2025-05-14 | -9.77 |
| 2025-05-13 | -10.61 |
| 2025-05-12 | -11.04 |
| 2025-05-09 | -9.93 |
| 2025-05-08 | -10.36 |
| 2025-05-07 | -11.10 |
| 2025-05-06 | -20.38 |
| 2025-05-05 | -21.71 |
| 2025-05-02 | -21.28 |
| 2025-05-01 | -19.95 |
| 2025-04-30 | -20.81 |
| 2025-04-29 | -20.16 |
| 2025-04-28 | -21.09 |
| 2025-04-25 | -20.84 |
| 2025-04-24 | -20.69 |
| 2025-04-23 | -20.44 |
| 2025-04-22 | -20.88 |
| 2025-04-21 | -20.78 |
| 2025-04-17 | -21.53 |
| 2025-04-16 | -22.36 |
| 2025-04-15 | -22.67 |
| 2025-04-14 | -22.89 |
| 2025-04-11 | -22.64 |
| 2025-04-10 | -22.48 |
| 2025-04-09 | -24.03 |
| 2025-04-08 | -21.80 |
| 2025-04-07 | -22.86 |
| 2025-04-04 | -23.04 |
| 2025-04-03 | -23.91 |